DREIMS
Financiado
DRUG-ELUTING ELECTRICAL IMPLANT TO REPAIR THE SPINAL CORD
In Neurofibres (FET-PROACTIVE, 2017-2021), we accomplished a major therapeutic advance for spinal cord injury (SCI) by combining biomaterials, pharmaceuticals, and electrical stimulation into an innovative implant able to promote...
In Neurofibres (FET-PROACTIVE, 2017-2021), we accomplished a major therapeutic advance for spinal cord injury (SCI) by combining biomaterials, pharmaceuticals, and electrical stimulation into an innovative implant able to promote the closure of the spinal cord gap, with axonal regrowth and glial cell migration across large lesions in rodent and porcine models of SCI. In brief, the implant comprised biofunctionalized, conducting polymer-coated carbon microfibres (MFs) that promoted aligned neural cell growth across the lesion, embedded within a drug-eluting hydrogel that filled the tissue defect and reduced fibrosis. These intraspinal elements were complemented with electrodes that provided biphasic electrical stimulation (ES) to the lesion and the perilesional tissue, thus inducing extensive neural regeneration.
Building on the initial proof of concept achieved in Neurofibres (TRL 3), DREIMS will mature this novel healthcare technology through TRLs 4-5, becoming close to its approval for use in human therapeutics while creating a business plan to support further exploitation steps. The inventors of the implant filled a patent application (P202230626) on the mentioned results and recently created a spin-off company (Spinal Cord Technologies, SCT S.L.) to pursue the refinement and validation of a successful clinical and commercial medical product. DREIMS builds on those results to consolidate the first-in-class drug-eluting electrical implant to repair the spinal cord. The implant will refine and integrate three modules, namely the microfiber/drug-eluting gel bundles (MIBs) from FUHNPAIIN / SCT S.L. (Spain), spinal electrode arrays (SEAs) from ALU-FR/IMTEK (Germany), and a fully implantable electric pulse generator (IPG) from NEURINNOV (France), thus forming a procedure pack according to the European Medical Device Regulation (MDR) 2017/745. Addressing regulatory requirements and business development activities will increase the market readiness of the implant.
ver más
Duración del proyecto: 37 meses
Fecha Inicio: 2023-10-06
Fecha Fin: 2026-11-30
Fecha Fin: 2026-11-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-10-06
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
Presupuesto
El presupuesto total del proyecto asciende a
3M€
Líder del proyecto
FUNDACIÓN HOSPITAL NACIONAL PARAPLÉJICOS PARA...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
802K
Perfil tecnológico
TRL
4-5
802K
706.04K€ |
Participante